Tumor-targeting Salmonella typhimurium A1-R suppressed an imatinib-resistant gastrointestinal stromal tumor with c-kit exon 11 and 17 mutations
Gastrointestinal stromal tumor (GIST) is a refractory disease in need of novel efficacious therapy. The aim of our study was to evaluate the effectiveness of tumor-targeting Salmonella typhimurium A1-R (S. typhimurium A1-R) using on a patient derived orthotopic xenograft (PDOX) model of imatinib-res...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2018-06-01
|
| Series: | Heliyon |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844018303414 |
| id |
doaj-a10b0dc2ca8c4a67a22ab4000f53aa9a |
|---|---|
| record_format |
Article |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Kentaro Miyake Kei Kawaguchi Masuyo Miyake Ming Zhao Tasuku Kiyuna Kentaro Igarashi Zhiying Zhang Takashi Murakami Yunfeng Li Scott D. Nelson Michael Bouvet Irmina Elliott Tara A. Russell Arun S. Singh Yukihiko Hiroshima Masashi Momiyama Ryusei Matsuyama Takashi Chishima Shree Ram Singh Itaru Endo Fritz C. Eilber Robert M. Hoffman |
| spellingShingle |
Kentaro Miyake Kei Kawaguchi Masuyo Miyake Ming Zhao Tasuku Kiyuna Kentaro Igarashi Zhiying Zhang Takashi Murakami Yunfeng Li Scott D. Nelson Michael Bouvet Irmina Elliott Tara A. Russell Arun S. Singh Yukihiko Hiroshima Masashi Momiyama Ryusei Matsuyama Takashi Chishima Shree Ram Singh Itaru Endo Fritz C. Eilber Robert M. Hoffman Tumor-targeting Salmonella typhimurium A1-R suppressed an imatinib-resistant gastrointestinal stromal tumor with c-kit exon 11 and 17 mutations Heliyon Biochemistry Cancer research Genetics Microbiology |
| author_facet |
Kentaro Miyake Kei Kawaguchi Masuyo Miyake Ming Zhao Tasuku Kiyuna Kentaro Igarashi Zhiying Zhang Takashi Murakami Yunfeng Li Scott D. Nelson Michael Bouvet Irmina Elliott Tara A. Russell Arun S. Singh Yukihiko Hiroshima Masashi Momiyama Ryusei Matsuyama Takashi Chishima Shree Ram Singh Itaru Endo Fritz C. Eilber Robert M. Hoffman |
| author_sort |
Kentaro Miyake |
| title |
Tumor-targeting Salmonella typhimurium A1-R suppressed an imatinib-resistant gastrointestinal stromal tumor with c-kit exon 11 and 17 mutations |
| title_short |
Tumor-targeting Salmonella typhimurium A1-R suppressed an imatinib-resistant gastrointestinal stromal tumor with c-kit exon 11 and 17 mutations |
| title_full |
Tumor-targeting Salmonella typhimurium A1-R suppressed an imatinib-resistant gastrointestinal stromal tumor with c-kit exon 11 and 17 mutations |
| title_fullStr |
Tumor-targeting Salmonella typhimurium A1-R suppressed an imatinib-resistant gastrointestinal stromal tumor with c-kit exon 11 and 17 mutations |
| title_full_unstemmed |
Tumor-targeting Salmonella typhimurium A1-R suppressed an imatinib-resistant gastrointestinal stromal tumor with c-kit exon 11 and 17 mutations |
| title_sort |
tumor-targeting salmonella typhimurium a1-r suppressed an imatinib-resistant gastrointestinal stromal tumor with c-kit exon 11 and 17 mutations |
| publisher |
Elsevier |
| series |
Heliyon |
| issn |
2405-8440 |
| publishDate |
2018-06-01 |
| description |
Gastrointestinal stromal tumor (GIST) is a refractory disease in need of novel efficacious therapy. The aim of our study was to evaluate the effectiveness of tumor-targeting Salmonella typhimurium A1-R (S. typhimurium A1-R) using on a patient derived orthotopic xenograft (PDOX) model of imatinib-resistant GIST. The GIST was obtained from a patient with regional recurrence, and implanted in the anterior gastric wall of nude mice. The GIST PDOX mice were randomized into 3 groups of 6 mice each when the tumor volume reached 60 mm3: G1, control group; G2, imatinib group (oral administration [p.o.], daily, for 3 weeks); G3, S. typhimurium A1-R group (intravenous [i.v.] injection, weekly, for 3 weeks). All mice from each group were sacrificed on day 22. Relative tumor volume was estimated by laparotomy on day 0 and day 22. Body weight of the mouse was evaluated 2 times per week. We found that S. typhimurium A1-R significantly reduced tumor growth in contrast to the untreated group (P = 0.001). In addition, we found that S. typhimurium A1-R was more effective compared to imatinib (P = 0.013). Furthermore, Imatinib was not significantly effective compared to the control group (P = 0.462). These results indicate that S. typhimurium A1-R may be new effective therapy for imatinib-resistant GIST and therefore a good candidate for clinical development of this disease. |
| topic |
Biochemistry Cancer research Genetics Microbiology |
| url |
http://www.sciencedirect.com/science/article/pii/S2405844018303414 |
| work_keys_str_mv |
AT kentaromiyake tumortargetingsalmonellatyphimuriuma1rsuppressedanimatinibresistantgastrointestinalstromaltumorwithckitexon11and17mutations AT keikawaguchi tumortargetingsalmonellatyphimuriuma1rsuppressedanimatinibresistantgastrointestinalstromaltumorwithckitexon11and17mutations AT masuyomiyake tumortargetingsalmonellatyphimuriuma1rsuppressedanimatinibresistantgastrointestinalstromaltumorwithckitexon11and17mutations AT mingzhao tumortargetingsalmonellatyphimuriuma1rsuppressedanimatinibresistantgastrointestinalstromaltumorwithckitexon11and17mutations AT tasukukiyuna tumortargetingsalmonellatyphimuriuma1rsuppressedanimatinibresistantgastrointestinalstromaltumorwithckitexon11and17mutations AT kentaroigarashi tumortargetingsalmonellatyphimuriuma1rsuppressedanimatinibresistantgastrointestinalstromaltumorwithckitexon11and17mutations AT zhiyingzhang tumortargetingsalmonellatyphimuriuma1rsuppressedanimatinibresistantgastrointestinalstromaltumorwithckitexon11and17mutations AT takashimurakami tumortargetingsalmonellatyphimuriuma1rsuppressedanimatinibresistantgastrointestinalstromaltumorwithckitexon11and17mutations AT yunfengli tumortargetingsalmonellatyphimuriuma1rsuppressedanimatinibresistantgastrointestinalstromaltumorwithckitexon11and17mutations AT scottdnelson tumortargetingsalmonellatyphimuriuma1rsuppressedanimatinibresistantgastrointestinalstromaltumorwithckitexon11and17mutations AT michaelbouvet tumortargetingsalmonellatyphimuriuma1rsuppressedanimatinibresistantgastrointestinalstromaltumorwithckitexon11and17mutations AT irminaelliott tumortargetingsalmonellatyphimuriuma1rsuppressedanimatinibresistantgastrointestinalstromaltumorwithckitexon11and17mutations AT taraarussell tumortargetingsalmonellatyphimuriuma1rsuppressedanimatinibresistantgastrointestinalstromaltumorwithckitexon11and17mutations AT arunssingh tumortargetingsalmonellatyphimuriuma1rsuppressedanimatinibresistantgastrointestinalstromaltumorwithckitexon11and17mutations AT yukihikohiroshima tumortargetingsalmonellatyphimuriuma1rsuppressedanimatinibresistantgastrointestinalstromaltumorwithckitexon11and17mutations AT masashimomiyama tumortargetingsalmonellatyphimuriuma1rsuppressedanimatinibresistantgastrointestinalstromaltumorwithckitexon11and17mutations AT ryuseimatsuyama tumortargetingsalmonellatyphimuriuma1rsuppressedanimatinibresistantgastrointestinalstromaltumorwithckitexon11and17mutations AT takashichishima tumortargetingsalmonellatyphimuriuma1rsuppressedanimatinibresistantgastrointestinalstromaltumorwithckitexon11and17mutations AT shreeramsingh tumortargetingsalmonellatyphimuriuma1rsuppressedanimatinibresistantgastrointestinalstromaltumorwithckitexon11and17mutations AT itaruendo tumortargetingsalmonellatyphimuriuma1rsuppressedanimatinibresistantgastrointestinalstromaltumorwithckitexon11and17mutations AT fritzceilber tumortargetingsalmonellatyphimuriuma1rsuppressedanimatinibresistantgastrointestinalstromaltumorwithckitexon11and17mutations AT robertmhoffman tumortargetingsalmonellatyphimuriuma1rsuppressedanimatinibresistantgastrointestinalstromaltumorwithckitexon11and17mutations |
| _version_ |
1724707708663234560 |
| spelling |
doaj-a10b0dc2ca8c4a67a22ab4000f53aa9a2020-11-25T02:58:13ZengElsevierHeliyon2405-84402018-06-0146e00643Tumor-targeting Salmonella typhimurium A1-R suppressed an imatinib-resistant gastrointestinal stromal tumor with c-kit exon 11 and 17 mutationsKentaro Miyake0Kei Kawaguchi1Masuyo Miyake2Ming Zhao3Tasuku Kiyuna4Kentaro Igarashi5Zhiying Zhang6Takashi Murakami7Yunfeng Li8Scott D. Nelson9Michael Bouvet10Irmina Elliott11Tara A. Russell12Arun S. Singh13Yukihiko Hiroshima14Masashi Momiyama15Ryusei Matsuyama16Takashi Chishima17Shree Ram Singh18Itaru Endo19Fritz C. Eilber20Robert M. Hoffman21AntiCancer Inc., San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA; Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, JapanAntiCancer Inc., San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USAAntiCancer Inc., San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA; Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, JapanAntiCancer Inc., San Diego, CA, USAAntiCancer Inc., San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USAAntiCancer Inc., San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USAAntiCancer Inc., San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USADepartment of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, JapanDeptartment of Pathology, University of California, Los Angeles, CA, USADeptartment of Pathology, University of California, Los Angeles, CA, USADepartment of Surgery, University of California, San Diego, CA, USADivision of Surgical Oncology, University of California, Los Angeles, CA, USADivision of Surgical Oncology, University of California, Los Angeles, CA, USADivision of Hematology-Oncology, University of California, Los Angeles, CA, USADepartment of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, JapanDepartment of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, JapanDepartment of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, JapanDepartment of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, JapanBasic Research Laboratory, National Cancer Institute, Frederick, MD, USA; Corresponding authors.Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan; Corresponding authors.Division of Surgical Oncology, University of California, Los Angeles, CA, USA; Corresponding authors.AntiCancer Inc., San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA; Corresponding authors.Gastrointestinal stromal tumor (GIST) is a refractory disease in need of novel efficacious therapy. The aim of our study was to evaluate the effectiveness of tumor-targeting Salmonella typhimurium A1-R (S. typhimurium A1-R) using on a patient derived orthotopic xenograft (PDOX) model of imatinib-resistant GIST. The GIST was obtained from a patient with regional recurrence, and implanted in the anterior gastric wall of nude mice. The GIST PDOX mice were randomized into 3 groups of 6 mice each when the tumor volume reached 60 mm3: G1, control group; G2, imatinib group (oral administration [p.o.], daily, for 3 weeks); G3, S. typhimurium A1-R group (intravenous [i.v.] injection, weekly, for 3 weeks). All mice from each group were sacrificed on day 22. Relative tumor volume was estimated by laparotomy on day 0 and day 22. Body weight of the mouse was evaluated 2 times per week. We found that S. typhimurium A1-R significantly reduced tumor growth in contrast to the untreated group (P = 0.001). In addition, we found that S. typhimurium A1-R was more effective compared to imatinib (P = 0.013). Furthermore, Imatinib was not significantly effective compared to the control group (P = 0.462). These results indicate that S. typhimurium A1-R may be new effective therapy for imatinib-resistant GIST and therefore a good candidate for clinical development of this disease.http://www.sciencedirect.com/science/article/pii/S2405844018303414BiochemistryCancer researchGeneticsMicrobiology |